Cargando…
The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
BACKGROUND: Driving ability is a key function for the majority of patients with multiple sclerosis (MS) to help maintain daily interactions. Both physical and cognitive disability, as well as treatments, may affect the ability to drive. Spasticity is a common symptom associated with MS, and it may a...
Autores principales: | Celius, Elisabeth G., Vila, Carlos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943754/ https://www.ncbi.nlm.nih.gov/pubmed/29761015 http://dx.doi.org/10.1002/brb3.962 |
Ejemplares similares
-
The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019) -
Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
por: Flachenecker, Peter, et al.
Publicado: (2018) -
A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020) -
A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity
por: Marinelli, Lucio, et al.
Publicado: (2017) -
An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray
por: Etges, Tilden, et al.
Publicado: (2016)